Canada · Delayed Price · Currency is CAD Pfizer Statistics
Total Valuation
Pfizer has a market cap or net worth of CAD 208.24 billion. The enterprise value is 272.85 billion.
| Market Cap | 208.24B |
| Enterprise Value | 272.85B |
Important Dates
The last earnings date was Tuesday, February 3, 2026.
| Earnings Date | Feb 3, 2026 |
| Ex-Dividend Date | Jan 23, 2026 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.23% |
| Shares Change (QoQ) | -0.49% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 66.22% |
| Float | 5.68B |
Valuation Ratios
The trailing PE ratio is 19.54 and the forward PE ratio is 8.98.
| PE Ratio | 19.54 |
| Forward PE | 8.98 |
| PS Ratio | 2.43 |
| PB Ratio | 1.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 25.61 |
| EV / Sales | 3.19 |
| EV / EBITDA | 7.77 |
| EV / EBIT | 10.41 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.67 |
| Debt / EBITDA | 2.41 |
| Debt / FCF | n/a |
| Interest Coverage | 7.17 |
Financial Efficiency
Return on equity (ROE) is 8.58% and return on invested capital (ROIC) is 13.68%.
| Return on Equity (ROE) | 8.58% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 13.68% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.06M |
| Profits Per Employee | 131,543 |
| Employee Count | 81,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -364.72M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -0.49% |
| 50-Day Moving Average | 11.59 |
| 200-Day Moving Average | 11.25 |
| Relative Strength Index (RSI) | 59.10 |
| Average Volume (20 Days) | 73,884 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.17 |
Income Statement
In the last 12 months, Pfizer had revenue of CAD 85.80 billion and earned 10.65 billion in profits. Earnings per share was 1.87.
| Revenue | 85.80B |
| Gross Profit | 65.04B |
| Operating Income | 26.27B |
| Pretax Income | 10.31B |
| Net Income | 10.65B |
| EBITDA | 35.22B |
| EBIT | 26.27B |
| Earnings Per Share (EPS) | 1.87 |
Balance Sheet
The company has 20.55 billion in cash and 84.92 billion in debt, with a net cash position of -64.38 billion.
| Cash & Cash Equivalents | 20.55B |
| Total Debt | 84.92B |
| Net Cash | -64.38B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 127.65B |
| Book Value Per Share | 22.38 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 75.81%, with operating and profit margins of 30.62% and 12.42%.
| Gross Margin | 75.81% |
| Operating Margin | 30.62% |
| Pretax Margin | 12.02% |
| Profit Margin | 12.42% |
| EBITDA Margin | 41.05% |
| EBIT Margin | 30.62% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.78, which amounts to a dividend yield of 6.67%.
| Dividend Per Share | 0.78 |
| Dividend Yield | 6.67% |
| Dividend Growth (YoY) | -0.46% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -0.23% |
| Shareholder Yield | 6.44% |
| Earnings Yield | 5.12% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |